<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00834808</url>
  </required_header>
  <id_info>
    <org_study_id>MDT1-011</org_study_id>
    <nct_id>NCT00834808</nct_id>
  </id_info>
  <brief_title>A Dose Linearity Study of the Labopharm Formulation of Tramadol HCl/ContramidÂ®, 100 mg, 200 mg and 300 mg After A Single Oral Administration In Fasting Condition, In Healthy Human Volunteers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Labopharm Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Labopharm Inc.</source>
  <brief_summary>
    <textblock>
      The purposes of this study were:

        -  To evaluate the plasma pharmacokinetic profile of tramadol and its principal metabolite,
           the O-desmethyltramadol, after a single oral administration of 100, 200 and 300 mg of
           tramadol as the Labopharm extended-release formulation prepared with Contramid.

        -  To assess the dose linearity of tramadol and its principal metabolite, the
           O-desmethyltramadol, between 100 mg and 300 mg following a single dose administration of
           the Labopharm extended-release formulation prepared with Contramid under fasting
           conditions in young healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">December 2002</completion_date>
  <primary_completion_date type="Actual">December 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC(0-t)</measure>
    <time_frame>48 hours</time_frame>
    <description>Area under the plasma concentration versus time curve to the last measurable concentration.
h = hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-inf)</measure>
    <time_frame>48 hours</time_frame>
    <description>Area under the plasma concentration versus time curve extrapolated to infinity. h = hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>48 hours</time_frame>
    <description>Maximum plasma concentration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>48 hours</time_frame>
    <description>Time to maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>48 hours</time_frame>
    <description>Apparent terminal elimination half-life</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1: Tramadol HCl 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2: Tramadol HCl 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3: Tramadol HCl 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol HCl</intervention_name>
    <description>One single oral administration of Tramadol HCl 100 mg, 200 mg or 300 mg as per randomization schedule.</description>
    <arm_group_label>1: Tramadol HCl 100mg</arm_group_label>
    <arm_group_label>2: Tramadol HCl 200mg</arm_group_label>
    <arm_group_label>3: Tramadol HCl 300mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Availability of subject for the entire study period and willingness to adhere to
             protocol requirements as evidenced by the informed consent form duly signed by the
             subject.

          -  Males aged from 18 to 45 years inclusively and with Body Mass Index (BMI) between 18
             and 30 kg/m2 inclusively.

          -  Clinical laboratory values within 10% above or below the laboratory's stated normal
             range; if not within this range, the clinical investigator will decide if they were
             not clinically significant and recorded this fact on the Case Report Form (CRF).

          -  Healthy according to the physical examination and laboratory results.

          -  Normal cardiovascular function according to a 12-lead electrocardiogram (ECG).

          -  Non-smoker or subjects smoking no more than 5 cigarettes per day (or equivalent) and
             able to abstain from smoking during inpatient phases of the study.

          -  Subjects covered by Social Security in compliance with the recommendations of French
             Law relating to biomedical research.

          -  Subjects with normal dietary requirements (neither vegetarian, nor on a diet).

        Exclusion Criteria:

          -  History of hypersensitivity to tramadol or any other compounds.

          -  Presence or significant history of gastrointestinal, liver or kidney disease, or any
             other conditions known to interfere with the absorption, distribution, metabolism or
             excretion of drugs.

          -  Presence or significant history of cardiovascular, pulmonary, haematological,
             neoplasic, neurological, psychiatric, endocrine, immunological or dermatological
             disease.

          -  Presence or significant history of glaucoma.

          -  Supine pulse rate lower than 45 beats per minute (bpm) after 5 minutes at rest or
             higher than 100 bpm.

          -  History of hypotensive episodes or a standing systolic blood pressure reading of &lt;100
             mmHg or a diastolic reading of &lt;45 mmHg, measured on the screening day.

          -  History of hypertensive episodes or a supine systolic blood pressure reading of &gt;145
             mmHg or a diastolic reading of &gt;95 mmHg, measured on the screening day.

          -  Presence of atrioventricular (AV) block assessed during pre-study evaluation or during
             the study. The lower limit considered for a first degree AV block was be a PR interval
             of 200 millisecond (msec).

          -  Maintenance therapy with any drug, or history of drug dependency, alcohol abuse (&gt;3
             units of alcohol per day), or serious psychological disease.

          -  Subjects consuming large quantities of drinks containing xanthine bases (coffee, tea,
             chocolate or cola; more than 6 cups or glasses per day).

          -  Any clinically significant illness in the previous 21 days before day 1 of this study.

          -  Subjects who had undergone general anesthesia within 3 months prior to the present
             study.

          -  Use of drugs known to affect liver enzymes (eg, inducers or inhibitors of Cytochrome
             P450) in the previous 30 days before day 1 of this study (eg, all barbiturates,
             corticosteroids, di &amp; methyl-phenylhydantoin).

          -  Use of any medication (including OTC preparations) in the previous 14 days before day
             1 of this study.

          -  Donation of 350 mL (or more) of blood in the previous 3 months or participation in
             another clinical trial in the previous 3 months before day 1 of this study.

          -  Subjects undergoing dental care.

          -  Positive urine drug screening.

          -  Positive results to human immunodeficiency virus (HIV) 1 &amp; 2 or hepatitis B surface
             antigen (HBsAg) or anti-HCV (hepatitis C virus) tests.

          -  History of fainting upon blood sampling.

          -  Evidence of psychiatric disorder, antagonistic personality, poor motivation, emotional
             or intellectual problems likely to limit the validity of the consent to participate in
             the study or to limit the ability to comply with the protocol requirements.

          -  Subjects unable to abstain from intensive muscular effort or sport competitions during
             the week prior to the study and throughout the study itself.

          -  Subjects who had forfeited his freedom by administrative or legal award or who were
             under guardianship.

          -  Subjects who received the ceiling amount of 25,000 francs within the last 12 months or
             who reached this ceiling with the payment of this allowance for this study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=9048</url>
    <description>Approved labelling</description>
  </link>
  <results_reference>
    <citation>Karhu D, El-Jammal A, Dupain T, Gaulin D, Bouchard S. Pharmacokinetics and dose proportionality of three Tramadol Contramid OAD tablet strengths. Biopharm Drug Dispos. 2007 Sep;28(6):323-30.</citation>
    <PMID>17575561</PMID>
  </results_reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2009</study_first_submitted>
  <study_first_submitted_qc>February 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2009</study_first_posted>
  <results_first_submitted>April 8, 2009</results_first_submitted>
  <results_first_submitted_qc>April 8, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 2, 2009</results_first_posted>
  <last_update_submitted>April 24, 2012</last_update_submitted>
  <last_update_submitted_qc>April 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2012</last_update_posted>
  <responsible_party>
    <name_title>Vice-President Regulatory Affairs</name_title>
    <organization>Labopharm Inc.</organization>
  </responsible_party>
  <keyword>Healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1: Tramadol HCl 100mg</title>
          <description>Single oral administration fasting conditions.
Randomization schedule based on a Latin Square design.</description>
        </group>
        <group group_id="P2">
          <title>2: Tramadol HCl 200mg</title>
          <description>Single oral administration fasting conditions.
Randomization schedule based on a Latin Square design.</description>
        </group>
        <group group_id="P3">
          <title>3: Tramadol HCl 300mg</title>
          <description>Single oral administration fasting conditions.
Randomization schedule based on a Latin Square design.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1 (Day 1)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 2 (Day 8)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 3 (Day 15)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1: Tramadol HCl 100mg</title>
          <description>Single oral administration fasting conditions.
Randomization schedule based on a Latin Square design.</description>
        </group>
        <group group_id="B2">
          <title>2: Tramadol HCl 200mg</title>
          <description>Single oral administration fasting conditions.
Randomization schedule based on a Latin Square design.</description>
        </group>
        <group group_id="B3">
          <title>3: Tramadol HCl 300mg</title>
          <description>Single oral administration fasting conditions.
Randomization schedule based on a Latin Square design.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-t)</title>
        <description>Area under the plasma concentration versus time curve to the last measurable concentration.
h = hours</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1: Tramadol HCl 100mg</title>
            <description>Single oral administration fasting conditions.
Randomization schedule based on a Latin Square design.</description>
          </group>
          <group group_id="O2">
            <title>2: Tramadol HCl 200mg</title>
            <description>Single oral administration fasting conditions.
Randomization schedule based on a Latin Square design.</description>
          </group>
          <group group_id="O3">
            <title>3: Tramadol HCl 300mg</title>
            <description>Single oral administration fasting conditions.
Randomization schedule based on a Latin Square design.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-t)</title>
          <description>Area under the plasma concentration versus time curve to the last measurable concentration.
h = hours</description>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2064" spread="707"/>
                    <measurement group_id="O2" value="4332" spread="1149"/>
                    <measurement group_id="O3" value="6568" spread="2050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-inf)</title>
        <description>Area under the plasma concentration versus time curve extrapolated to infinity. h = hours</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1: Tramadol HCl 100mg</title>
            <description>Single oral administration fasting conditions.
Randomization schedule based on a Latin Square design.</description>
          </group>
          <group group_id="O2">
            <title>2: Tramadol HCl 200mg</title>
            <description>Single oral administration fasting conditions.
Randomization schedule based on a Latin Square design.</description>
          </group>
          <group group_id="O3">
            <title>3: Tramadol HCl 300mg</title>
            <description>Single oral administration fasting conditions.
Randomization schedule based on a Latin Square design.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-inf)</title>
          <description>Area under the plasma concentration versus time curve extrapolated to infinity. h = hours</description>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2108" spread="731"/>
                    <measurement group_id="O2" value="4416" spread="1192"/>
                    <measurement group_id="O3" value="6741" spread="2156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax</title>
        <description>Maximum plasma concentration.</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1: Tramadol HCl 100mg</title>
            <description>Single oral administration fasting conditions.
Randomization schedule based on a Latin Square design.</description>
          </group>
          <group group_id="O2">
            <title>2: Tramadol HCl 200mg</title>
            <description>Single oral administration fasting conditions.
Randomization schedule based on a Latin Square design.</description>
          </group>
          <group group_id="O3">
            <title>3: Tramadol HCl 300mg</title>
            <description>Single oral administration fasting conditions.
Randomization schedule based on a Latin Square design.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>Maximum plasma concentration.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" spread="27"/>
                    <measurement group_id="O2" value="197" spread="58"/>
                    <measurement group_id="O3" value="290" spread="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax</title>
        <description>Time to maximum plasma concentration</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1: Tramadol HCl 100mg</title>
            <description>Single oral administration fasting conditions.
Randomization schedule based on a Latin Square design.</description>
          </group>
          <group group_id="O2">
            <title>2: Tramadol HCl 200mg</title>
            <description>Single oral administration fasting conditions.
Randomization schedule based on a Latin Square design.</description>
          </group>
          <group group_id="O3">
            <title>3: Tramadol HCl 300mg</title>
            <description>Single oral administration fasting conditions.
Randomization schedule based on a Latin Square design.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax</title>
          <description>Time to maximum plasma concentration</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="3" upper_limit="16"/>
                    <measurement group_id="O2" value="5.5" lower_limit="3" upper_limit="16"/>
                    <measurement group_id="O3" value="5" lower_limit="3" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t1/2</title>
        <description>Apparent terminal elimination half-life</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1: Tramadol HCl 100mg</title>
            <description>Single oral administration fasting conditions.
Randomization schedule based on a Latin Square design.</description>
          </group>
          <group group_id="O2">
            <title>2: Tramadol HCl 200mg</title>
            <description>Single oral administration fasting conditions.
Randomization schedule based on a Latin Square design.</description>
          </group>
          <group group_id="O3">
            <title>3: Tramadol HCl 300mg</title>
            <description>Single oral administration fasting conditions.
Randomization schedule based on a Latin Square design.</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2</title>
          <description>Apparent terminal elimination half-life</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="1.3"/>
                    <measurement group_id="O2" value="6.1" spread="1.3"/>
                    <measurement group_id="O3" value="6.3" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1: Tramadol HCl 100mg</title>
          <description>Single oral administration fasting conditions.
Randomization schedule based on a Latin Square design.</description>
        </group>
        <group group_id="E2">
          <title>2: Tramadol HCl 200mg</title>
          <description>Single oral administration fasting conditions.
Randomization schedule based on a Latin Square design.</description>
        </group>
        <group group_id="E3">
          <title>3: Tramadol HCl 300mg</title>
          <description>Single oral administration fasting conditions.
Randomization schedule based on a Latin Square design.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The publication of the results obtained will be authorized, after prior agreement between the various recipients [investigator and sponsor].</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Regulatory Affairs</name_or_title>
      <organization>Labopharm Inc.</organization>
      <phone>1 450 686 1017</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

